PureTech Health (LON:PRTC) Hits New 12-Month Low – Should You Sell?

Shares of PureTech Health plc (LON:PRTC) hit a new 52-week low during trading on Friday. The stock traded as low as GBX 107.20 and last traded at GBX 107.80, with a volume of 847011 shares traded. The stock had previously closed at GBX 110.60.

Analyst Ratings Changes

Separately, Peel Hunt reissued a “buy” rating and set a GBX 508 price objective on shares of PureTech Health in a research note on Monday, July 13th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of GBX 508.

PureTech Health Price Performance

The company has a current ratio of 4.60, a quick ratio of 2.51 and a debt-to-equity ratio of 4.78. The company’s 50 day moving average is GBX 119.36 and its 200-day moving average is GBX 123.60. The stock has a market cap of £264.30 million, a PE ratio of -2.34 and a beta of 0.77.

Insider Transactions at PureTech Health

In other PureTech Health news, insider John LaMattina acquired 93,944 shares of the stock in a transaction on Wednesday, July 29th. The stock was purchased at an average price of GBX 1 per share, for a total transaction of £939.44. Also, insider Michele Holcomb acquired 93,944 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were acquired at an average price of GBX 1 per share, for a total transaction of £939.44. Insiders have bought a total of 617,569 shares of company stock valued at $18,063,751 in the last three months. 13.41% of the stock is currently owned by company insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.